NOLVADEX Drug Patent Profile

Which patents cover Nolvadex, and when can generic versions of Nolvadex launch?

Nolvadex is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in NOLVADEX is tamoxifen citrate. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the tamoxifen citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nolvadex

A generic version of NOLVADEX was approved as tamoxifen citrate by ACTAVIS LABS FL INC on February 20^th, 2003.

Summary for NOLVADEX

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	75
DailyMed Link:	NOLVADEX at DailyMed

Recent Clinical Trials for NOLVADEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jose Pablo Leone	Phase 2
Translational Breast Cancer Research Consortium (TBCRC)	Phase 2
Eli Lilly and Company	Phase 2

See all NOLVADEX clinical trials

US Patents and Regulatory Information for NOLVADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	NOLVADEX	tamoxifen citrate	TABLET;ORAL	017970-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Astrazeneca	NOLVADEX	tamoxifen citrate	TABLET;ORAL	017970-002	Mar 21, 1994		DISCN	Yes	No

Expired US Patents for NOLVADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	NOLVADEX	tamoxifen citrate	TABLET;ORAL	017970-001	Approved Prior to Jan 1, 1982	4,536,516*PED
Astrazeneca	NOLVADEX	tamoxifen citrate	TABLET;ORAL	017970-002	Mar 21, 1994	4,536,516*PED

International Patents for NOLVADEX

See the table below for patents covering NOLVADEX around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	1013907
France	318
Switzerland	538447	Verfahren zur Herstellung der cis- oder trans-Isomeren von Alkenderivaten
Belgium	637389
Denmark	118655
Germany	1468088

Market Dynamics and Financial Trajectory for NOLVADEX (Tamoxifen)

Last updated: March 12, 2026

What Drives the Demand for NOLVADEX?

NOLVADEX (tamoxifen) is a selective estrogen receptor modulator (SERM) primarily used in breast cancer treatment and prevention. Its market relies heavily on breast cancer incidence, approval status, and prevailing treatment protocols.

Key Market Drivers:

• Breast cancer prevalence: An estimated 2.3 million new cases globally in 2020, with estrogen receptor-positive (ER+) types constituting approximately 70% (Source: WHO).
• Use in adjuvant therapy: Standard of care for ER+ breast cancer post-surgery, often prescribed for 5-10 years.
• Prevention indication: Recommended for high-risk individuals to reduce incidence.
• Emerging indications: Research into metastasis management, chemoprevention extension, and other cancers.

Market Challenges:

• Competition from aromatase inhibitors: Drugs like anastrozole, letrozole, and exemestane offer alternatives with differing efficacy profiles.
• Side effects: Risk of thromboembolic events and endometrial cancer limits patient compliance.
• Patent expirations: Generics gained market share after patent lapses, reducing prices.

Market Trends and Demand Dynamics

Geographic Variations:

• United States: Dominates market with established guidelines favoring tamoxifen and aromatase inhibitors, accounting for nearly 40% of global sales.
• Europe: Similar trends, with increased adoption of aromatase inhibitors.
• Emerging markets: Growing due to increased healthcare infrastructure and breast cancer screening programs.

Regulatory Factors:

• Regulatory approvals influence market size. Tamoxifen's patent expired in 2002, leading to widespread generic production.
• Ongoing evaluation for new indications influences future demand.

Pricing and Market Share:

Region	Brand/Gene ric	Price Range (USD per treatment course)	Market Share (Post-Patent)
U.S.	Nolvadex (original)	$100 - $300	Decreasing as generics dominate
Europe	Tamoxifen generic	$50 - $150	Growing
Emerging Markets	Local generics	$10 - $50	Rapid expansion

Forecasts:

• The global breast cancer treatment market projected to reach $21 billion by 2026, with tamoxifen contributing significantly.
• CAGR estimates range from 3-5% driven by increased screening and survivorship.

Financial Trajectory and Revenue Outlook

Historical Performance:

• The original patent (U.S.) expired in 2002.
• Peak global sales in 2005 exceeded $600 million (Source: EvaluatePharma).
• Post-generic introduction, annual sales declined but stabilized, with revenues hovering around $300 million to $400 million globally.

Current Financial Position:

• Sales fluctuate based on regional prescribing trends.
• Generic competition constrains margins.

Future Revenue Opportunities:

• New indications: Chemoprevention and metastatic disease management trials could expand use.
• Combination therapies: Trials combining tamoxifen with targeted agents may influence demand.
• Market expansion: Increased access in Asia and Africa.

Risk Factors:

• Competitive pressure from aromatase inhibitors.
• Regulatory delays or adverse trial outcomes.
• Patent challenges or legal decisions affecting exclusivity.

Competitive Landscape

Player	Product/Generic Name	Market Share (Global)	Notes
AstraZeneca (Original maker)	Nolvadex	Declined post-patent	Transitioned to generics, retains some branding value
Sandoz/Novartis	Generic Tamoxifen	~50% after patent expiry	Largest manufacturer of tamoxifen generics
Other Generics Companies	Multiple	Remaining share	Increased availability in low-cost markets

Regulatory and Policy Impact

• FDA & EMA: Approve tamoxifen for breast cancer treatment, with ongoing review for supplementary indications.
• Pricing policies: In some markets, price caps limit revenue potential.

Conclusion

The market for NOLVADEX is mature, with revenues impacted by generic competition. Future growth hinges on new clinical uses and expansion into underserved regions. The demand remains stable due to its established role in breast cancer therapy, but limited by evolving treatment paradigms favoring aromatase inhibitors.

---

Key Takeaways

• NOLVADEX's revenue peaked in the mid-2000s, declining due to patent expiry.
• Generics account for the majority of sales, especially outside the U.S.
• Market growth prospects are tied to new indications and geographic expansion.
• Competition from aromatase inhibitors limits NOLVADEX's market share.
• Pricing pressures and regulatory policies significantly influence revenues.

FAQs

1. Will NOLVADEX regain market share from aromatase inhibitors?
Unlikely. Aromatase inhibitors have become preferred in many cases due to superior efficacy in certain populations, limiting NOLVADEX's growth.

2. Are there ongoing research efforts to expand NOLVADEX's indications?
Yes. Clinical trials are investigating its role in metastatic settings and chemoprevention, which could influence future demand.

3. How do patent expirations affect NOLVADEX's pricing?
Patent expiration fosters generic entry, reducing prices and margins. Market share shifts towards low-cost generics.

4. What is the outlook for NOLVADEX in emerging markets?
Growing healthcare infrastructure and breast cancer screening initiatives may boost demand, especially as generic availability increases affordability.

5. What regulatory challenges could impact NOLVADEX's market?
Approval delays, trial outcomes, or legal disputes over independent indications could restrict or expand its use.

---

References

1. World Health Organization. (2022). Global Cancer Factsheet.
2. EvaluatePharma. (2019). Breast Cancer Market Trends.
3. U.S. Food and Drug Administration. (2021). Tamoxifen Label Information.
4. European Medicines Agency. (2020). Summary of Product Characteristics: Tamoxifen.
5. IMS Health. (2018). Global Oncology Market Report.